Delving into the Latest Updates on CanCure LLC with Synapse

概览

疾病领域	数量

肿瘤	5
血液及淋巴系统疾病	1
免疫系统疾病	1

排名前五的药物类型	数量

单克隆抗体	2
治疗性疫苗	1
小分子化药	1
生物药	1

排名前五的靶点	数量

MICA x MICB	2

关联

5

项与 CanCure LLC 相关的药物

CNC-118

靶点-

作用机制

免疫刺激剂

在研机构

CanCure LLC

原研机构

CanCure LLC

在研适应症

黑色素瘤

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

SYB-010

靶点

MICA x MICB

作用机制

MICA抑制剂 [+1]

在研机构

CanCure LLC

原研机构

CanCure LLC

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

CNC 332

靶点-

作用机制-

在研机构

CanCure LLC

原研机构

CanCure LLC

在研适应症

实体瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 CanCure LLC 相关的临床结果

登录后查看更多信息

0 项与 CanCure LLC 相关的专利（医药）

登录后查看更多信息

2

项与 CanCure LLC 相关的文献（医药）

2017-05-05·Science Advances1区 · 综合性期刊

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

1区 · 综合性期刊

ArticleOA

作者: Staveley-O’Carroll, Kevin F. ; Liu, Dai ; Li, Guangfu ; Li, Zihai ; Graff, Julie N. ; Wu, Jennifer D. ; Zhang, Jingyu

Cooperative therapeutic effect of anti-CTLA4 and anti-sMIC antibodies.

2016-01-05·Oncotarget

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC

Article

作者: Wu, Jennifer ; Wong, Hing ; Jeng, Emily K. ; Basher, Fahmin

Shedding of the human NKG2D ligand MIC (MHC class I-chain-related molecule) from tumor cell surfaces correlates with progression of many epithelial cancers. Shedding-derived soluble MIC (sMIC) enables tumor immune escape through multiple immune suppressive mechanisms, such as disturbing natural killer (NK) cell homeostatic maintenance, impairing NKG2D expression on NK cells and effector T cells, and facilitating the expansion of arginase I+ myeloid suppressor cells. Our recent study has demonstrated that sMIC is an effective cancer therapeutic target. Whether targeting tumor-derived sMIC would enhance current active immunotherapy is not known. Here, we determined the in vivo therapeutic effect of an antibody co-targeting sMIC with the immunostimulatory IL-15 superagonist complex, ALT-803, using genetically engineered transplantable syngeneic sMIC+ tumor models. We demonstrate that combined therapy of a nonblocking antibody neutralizing sMIC and ALT-803 improved the survival of animals bearing sMIC+ tumors in comparison to monotherapy. We further demonstrate that the enhanced therapeutic effect with combined therapy is through concurrent augmentation of NK and CD8 T cell anti-tumor responses. In particular, expression of activation-induced surface molecules and increased functional potential by cytokine secretion are improved greatly by the administration of combined therapy. Depletion of NK cells abolished the cooperative therapeutic effect. Our findings suggest that administration of the sMIC-neutralizing antibody can enhance the anti-tumor effects of ALT-803. With ALT-803 currently in clinical trials to treat progressive solid tumors, the majority of which are sMIC+, our findings provide a rationale for co-targeting sMIC to enhance the therapeutic efficacy of ALT-803 or other IL-15 agonists.

100 项与 CanCure LLC 相关的药物交易

登录后查看更多信息

100 项与 CanCure LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

4

1

临床2期

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CNC-118	黑色素瘤更多	临床2期
SYB-010 ( MICA x MICB )	肿瘤更多	临床前
CNC-225	肿瘤更多	临床前
CNC 332	实体瘤更多	临床前
B10G5 ( MICA x MICB )	转移性前列腺癌更多	临床前